BackNKGen Biotech- Warrants (01/09/2028) Overview
NKGen Biotech Inc - Warrants (01/09/2028)

NKGen Biotech- Warrants (01/09/2028) Return on Equity

Latest ROE for NKGen Biotech- Warrants (01/09/2028): 46.8% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

46.80%

Return on Equity

46.80%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

NKGen Biotech- Warrants (01/09/2028) (NKGNW) FAQ

NKGen Biotech- Warrants (01/09/2028) (NKGNW) currently reports a ROE of 46.8%. That is above the sector sector average of -6.04%. Use the charts on this page to explore NKGen Biotech- Warrants (01/09/2028)'s ROE history and peer comparisons.

NKGen Biotech- Warrants (01/09/2028)'s ROE of 46.8% is higher than the its sector sector average of -6.04%. That is roughly 874.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but NKGen Biotech- Warrants (01/09/2028)'s current 46.8% should be judged against industry norms (sector average: -6.04%) and against NKGNW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 46.8%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -6.04%. From there, open related valuation or income-statement pages for NKGen Biotech- Warrants (01/09/2028), and consider following NKGNW for alerts when major investors trade the stock.